Milestone Pharmaceuticals (MIST) Accumulated Expenses (2018 - 2026)

Milestone Pharmaceuticals' Accumulated Expenses history runs 9 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• Quarterly Accumulated Expenses changed 0.43% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (changed 0.43% YoY) and the FY2025 annual result came in at $7.6 million, up 205.64% from the prior year.
• Accumulated Expenses was $1.2 million for Q1 2026 at Milestone Pharmaceuticals, down from $7.6 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $7.6 million in Q4 2025 and bottomed at $527000.0 in Q2 2022.
• A 5-year average of $1.9 million and a median of $1.9 million in 2022 frame the typical range for Accumulated Expenses.
• Peak annual rise in Accumulated Expenses reached 258.06% in 2023, while the deepest fall reached 72.33% in 2023.
• Milestone Pharmaceuticals' Accumulated Expenses stood at $2.6 million in 2022, then sank by 72.33% to $712000.0 in 2023, then jumped by 251.26% to $2.5 million in 2024, then soared by 205.64% to $7.6 million in 2025, then slumped by 84.9% to $1.2 million in 2026.
• Business Quant data shows MIST's Accumulated Expenses at $1.2 million in Q1 2026, $7.6 million in Q4 2025, and $2.4 million in Q3 2025.